RZLT (Rezolute) E10: $-14.87 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RZLT Rezolute Inc RZLT
34 GF Score
Price $5.09
! 1 Warning Sign
View Full Analysis

What is Rezolute E10?

Rezolute RZLT +9.11% 34 E10 is $-14.87 as of Mar. 2026. GuruFocus rates RZLT with a GF Score™ of 34/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Rezolute's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.160. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-14.87 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Rezolute was 19.80% per year. The lowest was 13.10% per year. And the median was 16.45% per year.

As of today (2026-08-23), Rezolute's current stock price is $5.09. Rezolute's E10 for the quarter that ended in Mar. 2026 was $-14.87. Rezolute's Shiller PE Ratio of today is .


Rezolute  (NAS:RZLT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Rezolute E10 Related Terms


Rezolute E10 Historical Data

* Premium members only.

The historical data trend for Rezolute's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rezolute E10 Chart

Rezolute Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -31.41 -34.10 -28.06 -20.62 -17.59

Rezolute Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.22 -17.59 -16.78 -15.60 -14.87

RZLT vs DNA, EIKN, ARTV: E10 Comparison

For the Biotechnology subindustry, Rezolute's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Rezolute's Shiller PE Ratio falls into.


RZLT
34GF Score
Rezolute Inc RZLT
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rezolute E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Rezolute's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.16/330.2130*330.2130
=-0.160

Current CPI (Mar. 2026) = 330.2130.

Rezolute Quarterly Data

per share eps CPI Adj_EPS
201606 -19.000 241.018 -26.031
201609 -5.500 241.428 -7.523
201612 -6.000 241.432 -8.206
201703 -10.500 243.801 -14.222
201706 -6.500 244.955 -8.762
201709 -6.500 246.819 -8.696
201712 -5.500 246.524 -7.367
201803 -4.500 249.554 -5.954
201806 -11.000 251.989 -14.415
201809 -2.500 252.439 -3.270
201812 -3.500 251.233 -4.600
201903 -18.000 254.202 -23.382
201906 -0.748 256.143 -0.964
201909 -0.940 256.759 -1.209
201912 -1.140 256.974 -1.465
202003 -0.860 258.115 -1.100
202006 -0.610 257.797 -0.781
202009 -0.620 260.280 -0.787
202012 -0.880 260.474 -1.116
202103 -0.440 264.877 -0.549
202106 -0.780 271.696 -0.948
202109 -0.920 274.310 -1.107
202112 -0.800 278.802 -0.948
202203 -0.650 287.504 -0.747
202206 -0.402 296.311 -0.448
202209 -0.190 296.808 -0.211
202212 -0.260 296.797 -0.289
202303 -0.300 301.836 -0.328
202306 -0.250 305.109 -0.271
202309 -0.280 307.789 -0.300
202312 -0.270 306.746 -0.291
202403 -0.340 312.332 -0.359
202406 -0.440 314.175 -0.462
202409 -0.220 315.301 -0.230
202412 -0.220 315.605 -0.230
202503 -0.270 319.799 -0.279
202506 -0.260 322.561 -0.266
202509 -0.180 324.800 -0.183
202512 -0.220 324.054 -0.224
202603 -0.160 330.213 -0.160

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-14.87 mean?
Rezolute (RZLT) has a E10 of $-14.87 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rezolute and its competitors.
Is Rezolute's E10 too high?
Rezolute's current E10 is $-14.87. Overall, Rezolute has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Rezolute's E10 compare to DNA and EIKN?
Rezolute's E10 of $-14.87 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Rezolute and its competitors. Rezolute's current E10 is $-14.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rezolute stock overvalued right now?
Rezolute (RZLT) has a current E10 of $-14.87. The current E10 is $-14.87. Rezolute's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Rezolute (RZLT), the current E10 is $-14.87 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rezolute Business Description

Address 275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
34GF Score

Get the complete analysis for RZLT

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.09
Price